GALT on Nasdaq
GALECTIN THERAPEUTICS INC
American pharmaceutical preparations company based in Norcross. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerGALT on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersNorcross, United States2
- Incorporated inNV3
- Business address4960 Peachtree Industrial Boulevard, Suite 240, Norcross, Ga 300713
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI5299004HFYSAZM2ALW852
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered address701 S CARSON ST STE 200, 89701 Carson City, United States2
- Registered withBusiness Center (Secretary of State), NV200111970782
See how the biggest companies compare on our leaderboards
Our lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. Belapectin has the potential to treat many diseases due to galectin-3’s involvement in multiple key biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death). The importance of galectin-3 in the fibrotic process is supported by experimental evidence. Animals with the galectin-3 gene “knocked-out” can no longer develop fibrosis in response to experimental stimuli compared to animals with an intact galectin-3 gene. We are using our galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in MASH patients. We have completed two Phas…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $14.3M | $36.6M |
| General and administrative | $5.8M | $5.9M |
| Total operating expenses | $20.1M | $42.4M |
| Total operating loss | -$20.1M | -$42.4M |
| Interest income | $126.0K | $338.0K |
| Interest expense | -$7.3M | -$5.5M |
| Change in fair value of derivatives | -$3.5M | $588.0K |
| Total other expense | -$10.8M | -$4.6M |
| Net loss | -$30.8M | -$47.0M |
| Preferred stock dividends | -$138.0K | -$153.0K |
| Net loss applicable to common stockholders | -$31.0M | -$47.2M |
| Net loss per common share - basic (in Dollars per share) | -$0.48 | -$0.76 |
| Net loss per common share - diluted (in Dollars per share) | -$0.48 | -$0.76 |
| Weighted average common and potential common shares outstanding - basic (in Shares) | 63.9M shares | 62.3M shares |
| Weighted average common and potential common shares outstanding - diluted (in Shares) | 63.9M shares | 62.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.7M | $15.1M | |
| Prepaid expenses and other current assets | $1.7M | $2.1M | |
| Total current assets | $19.4M | $17.3M | |
| Other | $96.0K | $243.0K | |
| Total assets | $19.5M | $17.5M | |
| Accounts payable | $3.2M | $5.7M | |
| Accrued expenses | $4.7M | $8.2M | |
| Current portion of convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | $0 | $21.1M | |
| Current portion of derivative liabilities (Note 6) | $0 | $369.0K | |
| Accrued dividends payable | $63.0K | $63.0K | |
| Total current liabilities | $8.0M | $35.4M | |
| Convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | $32.7M | $10.7M | |
| Derivative liabilities (Note 6) | $4.0M | $47.0K | |
| Borrowing and accrued interest under convertible line of credit, net of debt discount related party (Note 10) | $101.0M | $74.4M | |
| Total liabilities | $145.7M | $120.6M | |
| Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at December 31, 2025 and 2024, redemption value: $7,966,000, liquidation value: $1,760,000 at December 31, 2025 | $1.7M | $1.7M | $1.7M |
| Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2025 and 2024, 20,000,000 shares designated at December 31, 2025 and 2024, respectively | $0 | $0 | |
| Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,210,000 and 1,235,000 issued and outstanding at December 31, 2025 and 2024, respectively, liquidation value $1,210,000 at December 31, 2025 | $490.0K | $500.0K | |
| Common stock, $0.001 par value; 150,000,000 shares authorized at December 31, 2025 and 2024, 65,201,995 and 63,157,235 issued and outstanding at December 31, 2025 and 2024, respectively | $65.0K | $62.0K | |
| Additional paid-in capital | $304.1M | $296.2M | |
| Accumulated deficit | -$432.5M | -$401.6M | |
| Total stockholders deficit | -$127.9M | -$104.8M | -$62.0M |
| Total liabilities, redeemable convertible preferred stock and stockholders deficit | $19.5M | $17.5M | |
| Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in Shares) | 1.0K shares | 1.0K shares | |
| Series C 6% super dividend redeemable convertible preferred stock, shares issued (in Shares) | 176 shares | 176 shares | |
| Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in Shares) | 176 shares | 176 shares | 176 shares |
| Series C 6% super dividend redeemable convertible preferred stock, redemption value | $8.0B | ||
| Series C 6% super dividend redeemable convertible preferred stock liquidation value | $1.8B | ||
| Undesignated stock, par value (in Dollars per share) | $0 | $0 | |
| Undesignated stock, shares authorized (in Shares) | 20.0M shares | 20.0M shares | |
| Undesignated stock, shares designated (in Shares) | 20.0M shares | 20.0M shares | |
| Series A 12% convertible preferred stock, shares authorized (in Shares) | 1.7M shares | 1.7M shares | |
| Series A 12% convertible preferred stock, shares issued (in Shares) | 1.2M shares | 1.2M shares | |
| Series A 12% convertible preferred stock, shares outstanding (in Shares) | 1.2M shares | 1.2M shares | |
| Series A 12% convertible preferred stock, liquidation value | $1.2B | ||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 150.0M shares | 150.0M shares | |
| Common stock, issued (in Shares) | 65.2M shares | 63.2M shares | |
| Common stock, outstanding (in Shares) | 65.2M shares | 63.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.7M | $15.1M | |
| Prepaid expenses and other current assets | $1.7M | $2.1M | |
| Total current assets | $19.4M | $17.3M | |
| Other | $96.0K | $243.0K | |
| Total assets | $19.5M | $17.5M | |
| Accounts payable | $3.2M | $5.7M | |
| Accrued expenses | $4.7M | $8.2M | |
| Current portion of convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | $0 | $21.1M | |
| Current portion of derivative liabilities (Note 6) | $0 | $369.0K | |
| Accrued dividends payable | $63.0K | $63.0K | |
| Total current liabilities | $8.0M | $35.4M | |
| Convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | $32.7M | $10.7M | |
| Derivative liabilities (Note 6) | $4.0M | $47.0K | |
| Borrowing and accrued interest under convertible line of credit, net of debt discount related party (Note 10) | $101.0M | $74.4M | |
| Total liabilities | $145.7M | $120.6M | |
| Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at December 31, 2025 and 2024, redemption value: $7,966,000, liquidation value: $1,760,000 at December 31, 2025 | $1.7M | $1.7M | $1.7M |
| Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2025 and 2024, 20,000,000 shares designated at December 31, 2025 and 2024, respectively | $0 | $0 | |
| Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,210,000 and 1,235,000 issued and outstanding at December 31, 2025 and 2024, respectively, liquidation value $1,210,000 at December 31, 2025 | $490.0K | $500.0K | |
| Common stock, $0.001 par value; 150,000,000 shares authorized at December 31, 2025 and 2024, 65,201,995 and 63,157,235 issued and outstanding at December 31, 2025 and 2024, respectively | $65.0K | $62.0K | |
| Additional paid-in capital | $304.1M | $296.2M | |
| Accumulated deficit | -$432.5M | -$401.6M | |
| Total stockholders deficit | -$127.9M | -$104.8M | -$62.0M |
| Total liabilities, redeemable convertible preferred stock and stockholders deficit | $19.5M | $17.5M | |
| Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in Shares) | 1.0K shares | 1.0K shares | |
| Series C 6% super dividend redeemable convertible preferred stock, shares issued (in Shares) | 176 shares | 176 shares | |
| Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in Shares) | 176 shares | 176 shares | 176 shares |
| Series C 6% super dividend redeemable convertible preferred stock, redemption value | $8.0B | ||
| Series C 6% super dividend redeemable convertible preferred stock liquidation value | $1.8B | ||
| Undesignated stock, par value (in Dollars per share) | $0 | $0 | |
| Undesignated stock, shares authorized (in Shares) | 20.0M shares | 20.0M shares | |
| Undesignated stock, shares designated (in Shares) | 20.0M shares | 20.0M shares | |
| Series A 12% convertible preferred stock, shares authorized (in Shares) | 1.7M shares | 1.7M shares | |
| Series A 12% convertible preferred stock, shares issued (in Shares) | 1.2M shares | 1.2M shares | |
| Series A 12% convertible preferred stock, shares outstanding (in Shares) | 1.2M shares | 1.2M shares | |
| Series A 12% convertible preferred stock, liquidation value | $1.2B | ||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 150.0M shares | 150.0M shares | |
| Common stock, issued (in Shares) | 65.2M shares | 63.2M shares | |
| Common stock, outstanding (in Shares) | 65.2M shares | 63.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$30.8M | -$47.0M |
| Amortization of right to use asset | $53.0K | $37.0K |
| Stock-based compensation expense | $1.7M | $2.4M |
| Non-cash interest expense | $1.1M | $1.1M |
| Change in fair value of derivatives | $3.5M | -$588.0K |
| Prepaid expenses and other assets | $416.0K | -$82.0K |
| Accrued interest on convertible notes payable and convertible line of credit related party | $6.2M | $4.4M |
| Accounts payable, accrued expenses and other liabilities | -$6.0M | -$2.1M |
| Net cash from operating activities | -$23.9M | -$41.8M |
| Net cash from investing activities | $0 | $0 |
| Net proceeds from convertible line of credit related party | $21.0M | $30.0M |
| Net proceeds from issuance of common stock | $3.2M | $0 |
| Net proceeds from exercise of common stock options and warrants | $2.2M | $1.2M |
| Net cash from financing activities | $26.5M | $31.2M |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | $2.6M | -$10.5M |
| Payment of preferred stock dividends in common stock | $138.0K | $91.0K |
| Common stock purchase warrants issued in connection with related party line of credit | $667.0K | $845.0K |
| Noncash right to use lease asset | $61.0K | $0 |
| Conversion of Series A preferred to common stock | $10.0K | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led GALECTIN THERAPEUTICS INC, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerHarold H. Shlevin Jun 18, 2018 to Jan 13, 202013
- Chief executive officerPeter G. Traber May 31, 2011 to Jun 15, 201814
- Chief executive officerTheodore Daniel Zucconi Feb 18, 2009 to May 28, 200915
- ChairJames C. Czirr Jun 30, 2011 to Feb 3, 201516
- PresidentPeter G. Traber May 31, 2011 to Jun 15, 201814
- PresidentTheodore Daniel Zucconi Dec 21, 2007 to Mar 26, 200917
- Chief financial officerJack W. Callicutt Jul 2, 2013 to now18
- Chief financial officerThomas McGauley May 25, 2012 to Jun 21, 201319
- Chief financial officerAnthony Don Squeglia Nov 9, 2007 to Feb 3, 201020
- Chief financial officerCarl Laurence Lueders Mar 13, 2006 to Mar 13, 200721
- Chief operating officerHarold H. Shlevin Aug 29, 2012 to Jun 14, 201822
- Chief operating officerMaureen Foley Mar 13, 2006 to Feb 3, 201023
Board members and other officers (27)
- Chief Medical OfficerKhurram Jamil Aug 5, 2024 to now24
- Chief Medical OfficerPol F. Boudes Mar 16, 2020 to Feb 7, 202425
- Ex. VP, Mfg. & Product Dev.Eliezer Zomer Mar 13, 2006 to Apr 24, 200926
- Board memberHenry Brem Mar 17, 2026 to now27
- Board memberBenjamin Carson Sr. Feb 7, 2024 to now28
- Board memberElissa J. Schwartz Mar 31, 2021 to now29
- Board memberRichard A. Zordani Jr. Mar 31, 2021 to now30
- Board memberHarold H. Shlevin Jan 13, 2020 to now31
- Board memberKary Eldred May 29, 2018 to now32
- Board memberHerman Paul Pressler Jun 3, 2011 to Jul 8, 201533
- Board memberJohn F. Mauldin Jun 3, 2011 to Dec 19, 201634
- Board memberKevin D. Freeman Jun 3, 2011 to now35
- Board memberMarc Rubin Oct 14, 2011 to Jan 27, 202536
- Board memberPeter G. Traber Feb 20, 2009 to Dec 6, 201637
- Board memberRod D. Martin Feb 20, 2009 to Jul 8, 201538
- Board memberJames C. Czirr Feb 25, 2009 to Dec 1, 202339
- Board memberArthur Greenberg Aug 26, 2009 to Dec 19, 201640
- Board memberJames Theophile Gourzis Feb 9, 2007 to Feb 11, 200941
- Board memberHenry Jemil Esber Mar 2, 2007 to Feb 11, 200942
- Board memberSydney Colin Neill Aug 24, 2007 to Jun 29, 201143
- Board memberTheodore Daniel Zucconi Sep 27, 2007 to Apr 18, 201844
- Board memberBurton C. Firtel Mar 13, 2006 to Mar 13, 200745
- Board memberDale H. Conaway Mar 13, 2006 to Feb 11, 200946
- Board memberEdgar Ben-Josef Mar 13, 2006 to Mar 13, 200647
- Board memberJerald K. Rome Mar 13, 2006 to Apr 1, 201348
- Board memberMildred S. Christian Mar 13, 2006 to Feb 27, 200949
- Board memberSteven Prelack Mar 13, 2006 to Dec 19, 201650
Former names
- PRO PHARMACEUTICALS INCSep 7, 2001 to May 26, 20113
Timeline
Filings
355 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 56 major events, 225 insider forms, 2 large holders, 52 other. The latest 20:
- Oct 13, 2026ARS EDGAR
- Oct 13, 2026DEFA14A EDGAR
- Oct 13, 2026DEF 14A EDGAR
- Oct 2, 2026PRE 14A EDGAR
- Aug 14, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 4, 2026SCHEDULE 13D/A EDGAR
- Aug 4, 20268-K CURRENT REPORT FILING EDGAR
- Aug 4, 20264 EDGAR
- Jul 16, 20264 EDGAR
- Jun 30, 20264 EDGAR
- Jun 30, 20264 EDGAR
- Jun 29, 2026144 EDGAR
- Jun 26, 2026144 EDGAR
- Jun 26, 2026144 EDGAR
- Jun 25, 20264 EDGAR
- Jun 23, 2026144 EDGAR
- Jun 23, 20268-K EDGAR
- May 28, 20264 EDGAR
- May 15, 20268-K EDGAR
The 355 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
105 open-market trades by officers, directors and large owners since October 2021: 44 buys and 61 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 14, 2026 | Jamil KhurramChief Medical Officer | Sale | 16,250 | $5.13 | $83.4K | Form 4 |
| Jun 29, 2026 | Shlevin Harold H.Director | Sale | 22,268 | $5.04 | $112.2K | Form 4 |
| Jun 29, 2026 | Jamil KhurramChief Medical Officer | Sale | 47,467 | $5.04 | $239.2K | Form 4 |
| Jun 26, 2026 | Shlevin Harold H.Director | Sale | 7,732 | $5.00 | $38.7K | Form 4 |
| Jun 26, 2026 | Jamil KhurramChief Medical Officer | Sale | 4,570 | $5.00 | $22.9K | Form 4 |
| Jun 23, 2026 | Jamil KhurramChief Medical Officer | Sale | 7,557 | $3.14 | $23.7K | Form 4 |
| May 26, 2026 | Jamil KhurramChief Medical Officer | Sale | 568 | $3.10 | $1.8K | Form 4 |
| Feb 6, 2026 | ELDRED KARYDirector | Buy | 300 | $2.70 | $810 | Form 4 |
| Jan 6, 2026 | LEWIS JOELPresident and CEO | Sale | 37,698 | $3.58 | $135.0K | Form 4 |
| Jan 6, 2026 | CALLICUTT JACK WChief Financial Officer | Sale | 20,354 | $3.67 | $74.7K | Form 4 |
| Jan 6, 2026 | Jamil KhurramChief Medical Officer | Sale | 21,446 | $3.65 | $78.3K | Form 4 |
| Jan 5, 2026 | LEWIS JOELPresident and CEO | Sale | 27,731 | $3.91 | $108.4K | Form 4 |
| Jan 5, 2026 | CALLICUTT JACK WChief Financial Officer | Sale | 25,732 | $3.90 | $100.4K | Form 4 |
| Jan 5, 2026 | Jamil KhurramChief Medical Officer | Sale | 25,499 | $3.90 | $99.4K | Form 4 |
| Jan 2, 2026 | LEWIS JOELPresident and CEO | Sale | 18,571 | $4.20 | $78.0K | Form 4 |
| Jan 2, 2026 | CALLICUTT JACK WChief Financial Officer | Sale | 13,914 | $4.20 | $58.4K | Form 4 |
| Jan 2, 2026 | Jamil KhurramChief Medical Officer | Sale | 13,055 | $4.20 | $54.8K | Form 4 |
| Dec 31, 2025 | Jamil KhurramChief Medical Officer | Sale | 8,125 | $4.07 | $33.1K | Form 4 |
| Dec 23, 2025 | FREEMAN KEVIN DDirector | Buy | 5,500 | $3.55 | $19.5K | Form 4 |
| Dec 23, 2025 | FREEMAN KEVIN DDirector | Buy | 5,500 | $3.55 | $19.5K | Form 4 |
All 105 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Richard E. UihleinSCHEDULE 13D/A, 1 filing Aug 4, 202651
- 10X Fund, L.P.SC 13D/A, 1 filing Dec 1, 202352
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 98. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 2,988,353 | $13.9M | 0.0% | +2,189,116 |
| Vanguard Capital Management LLC | 2,168,065 | $10.1M | 0.0% | +201,523 |
| Geode Capital Management, LLC | 1,308,394 | $6.1M | 0.0% | +695,608 |
| Osaic Holdings, Inc. | 1,203,725 | $5.6M | 0.0% | +81,055 |
| Marshall Wace, Llp | 831,010 | $3.9M | 0.0% | −388,902 |
| Wealthspire Advisors, LLC | 721,788 | $3.3M | 0.0% | No change |
| State Street Corp | 567,779 | $2.6M | 0.0% | +309,347 |
| Commonwealth Equity Services, LLC | 407,113 | $1.9M | 0.0% | +40,000 |
| Northern Trust Corp | 386,545 | $1.8M | 0.0% | +256,097 |
| Vanguard Fiduciary Trust Co | 366,476 | $1.7M | 0.0% | +62,235 |
| Vanguard Portfolio Management LLC | 327,766 | $1.5M | 0.0% | New |
| Two Sigma Investments, LP | 318,245 | $1.5M | 0.0% | −148,818 |
| LPL Financial LLC | 285,380 | $1.3M | 0.0% | +18,180 |
| Geneos Wealth Management Inc. | 240,427 | $1.1M | 0.0% | −500 |
| UBS Group AG | 219,319 | $1.0M | 0.0% | +39,578 |
| Retirement Guys Formula LLC | 211,053 | $979.3K | 0.4% | +23,991 |
| Citadel Advisors LLC | 198,701 | $922.0K | 0.0% | −91,659 |
| Sovran Advisors, LLC | 257,997 | $874.6K | 0.1% | +167 |
| Susquehanna International Group, Llp | 177,197 | $822.2K | 0.0% | −378,505 |
| National Bank Of Canada /fi/ | 167,900 | $779.1K | 0.0% | New |
| Blair William & Co/il | 149,283 | $692.7K | 0.0% | No change |
| Charles Schwab Investment Management Inc | 116,424 | $540.2K | 0.0% | +86,414 |
| Bank of New York Mellon Corp | 105,742 | $490.6K | 0.0% | New |
| HighTower Advisors, LLC | 94,125 | $436.7K | 0.0% | +750 |
| Morgan Stanley | 93,475 | $433.7K | 0.0% | −10,930 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARJames C. Czirr, Chair
- 17SEC EDGARTheodore Daniel Zucconi, President
- 18
- 19
- 20
- 21
- 22
- 23
- 24SEC EDGARKhurram Jamil, Chief Medical Officer
- 25SEC EDGARPol F. Boudes, Chief Medical Officer
- 26
- 27SEC EDGARHenry Brem, Board member
- 28SEC EDGARBenjamin Carson Sr., Board member
- 29SEC EDGARElissa J. Schwartz, Board member
- 30SEC EDGARRichard A. Zordani Jr., Board member
- 31SEC EDGARHarold H. Shlevin, Board member
- 32SEC EDGARKary Eldred, Board member
- 33SEC EDGARHerman Paul Pressler, Board member
- 34SEC EDGARJohn F. Mauldin, Board member
- 35SEC EDGARKevin D. Freeman, Board member
- 36SEC EDGARMarc Rubin, Board member
- 37SEC EDGARPeter G. Traber, Board member
- 38SEC EDGARRod D. Martin, Board member
- 39SEC EDGARJames C. Czirr, Board member
- 40SEC EDGARArthur Greenberg, Board member
- 41
- 42SEC EDGARHenry Jemil Esber, Board member
- 43SEC EDGARSydney Colin Neill, Board member
- 44
- 45SEC EDGARBurton C. Firtel, Board member
- 46SEC EDGARDale H. Conaway, Board member
- 47SEC EDGAREdgar Ben-Josef, Board member
- 48SEC EDGARJerald K. Rome, Board member
- 49SEC EDGARMildred S. Christian, Board member
- 50SEC EDGARSteven Prelack, Board member
- 51
- 52